PASADENA, Calif.--(BUSINESS WIRE)--
Arrowhead Research Corporation (ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at three upcoming scientific conferences.
Scheduled conference presentations in June include the following:
The 18th Annual Meeting of the RNA Society Davos, Switzerland, June 14, 2013
A workshop presentation titled, Development of Dynamic Polyconjugates for tissue-targeted delivery of siRNA, will be presented by Christine Wooddell, Ph.D., Senior Scientist;
4th RNAi Research & Therapeutics Conference San Francisco, CA, USA, June 21, 2013
A featured presentation titled, DPC Technology for siRNA Delivery: Moving from Platform to Pipeline, will be presented by David Lewis, Ph.D., Vice President, Biology;
The European CLINAM and ETPN Summit, Clinical Nanomedicine and Targeted Medicine Basel, Switzerland, June 26, 2013
An oral presentation titled, A Novel Hepatitis B Treatment with RNAi, will be presented by Christopher Anzalone, Ph.D., President and CEO.
About Arrowhead Research Corporation
See original here:
Arrowhead to Present at Upcoming Scientific Conferences